Epilepsy is a neurological condition which affects the nervous system and is also known as a seizure disorder. It is usually diagnosed after a person has had at least two seizures that were not caused by some known medical condition like alcohol withdrawal or extremely low blood sugar. A seizure is defined as an abnormal, disorderly discharging of the brain's nerve cells, resulting in a temporary disturbance of motor, sensory, or mental function.

About 2.7 million Americans have been treated for epilepsy in the past 5 years. That's 8 or 9 out of every 1,000 people.

Epilepsy Programs

Epliga™ (Controlled release Oxcarbazepine):

• Once-per-day anticonvulsant therapy designed to provide reduced side effects.
  
• Earlier this year, Supernus completed a proof-of-concept study where Epliga showed significant improvement in key adverse events compared to the reference product Trileptal®.
  
• Phase III studies were initiated in 2008.
  

Trokesa™ (Controlled release Topiramate):

• Once-per-day anticonvulsant therapy designed to provide reduced side effects.
  
• Program is targeted to enter Phase III in 2009.
  

SPN 802:

• Once-per-day anticonvulsant and bipolar therapy designed to provide reduced side effects.
  
• Completed proof of concept Phase I study.